Clinical Trial Search

Primary: Drug Liking: Peak Effect (Emax) — 50.9; 60.5; 51.3; 92.8 mm — p=0.0001

Primary: Participants Who Had Undetectable HIV-1 RNA Levels at Less Than 400 Copies/mL at Six Month — 45; 16 Participants — p=0.431

Primary: Overall Comfort — 58.74; 48.14; 57.32 Units on a scale

Primary: Change in Patient-reported Symptoms Measured by the 8-point Lee Eye Subscale — 75.4; 63.2; 61.8; 56.3 units on a scale — p=0.01

Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants

Primary: Number of Participants Who Achieved a Clinically Significant Improvement in the Oswestry Disability Index at 12 Months — 83; 35 Participants

Primary: Change in Cortical Gama-aminobutyric Acid Levels (GABA Levels) Pre and Post SSRI Treatment

Primary: Rate of Late Radiation Morbidity (≥ Grade 2 Lymphedema, Subcutaneous Fibrosis, or Joint Stiffness) at 2 Years From the Start of Radiotherapy as Measured by EORTC/RTOG…

Primary: Difference of Maximum Grip Strength — 03; 0; -02 Kilograms (Kg)

Primary: Number of Participants With Biochemically-verified Smoking Abstinence, Assessed 14 Times Over 8 Weeks — 3; 10; 3; 0 Participants

Primary: Change in Wolf Motor Function Test (WMFT), Timed Portion — -0.36; -0.18; -0.37; -0.15 log(seconds)

Primary: Steady-state Average Concentration (ssCavg) of Posaconazole on Day 8 — 0.0; 88.9; 11.1; 0 Percentage of Participants

Primary: Change Score for Z-height Baseline to Endpoint — -.04; -.11 Z score

Primary: Complete Response Rate at 20 Weeks — 45 percentage of participants

Primary: Dose Limiting Toxicities (DLTs) — 0 Participants